



*biologics*

an Open Access Journal by MDPI

## **Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes**

Guest Editors:

**Prof. Dr. Vasso Apostolopoulos**

Institute for Health and Sport,  
Victoria University, Melbourne,  
VIC 3011, Australia

**Dr. Vivek P. Chavda**

Department of Pharmaceutics  
and Pharmaceutical Technology,  
L M College of Pharmacy,  
Ahmedabad 380008, Gujarat,  
India

**Dr. Mahesh T. Chhabria**

L M College of Pharmacy,  
Ahmedabad, Gujarat, India

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### **Message from the Guest Editors**

Since the beginning of the pandemic, new “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” variants have emerged that can influence the airborne transmission, virulence, and immune evasion of affected individuals. The neutralizing antibodies produced as a result of vaccination or post-recovery of COVID-19 are not providing sufficient immune protection against emerging SARS-CoV-2 variants. SARS-CoV-2 variant-specific vaccines are required for better protection. A range of treatment options has become available, specifically for the aged, those with underlying health conditions, and the immunocompromised.

This Special Issue seeks all types of manuscripts (e.g., reviews, research articles, and short communications) on the impact of the aged population and immunocompromised patients on SARS-CoV-2 variants, vaccine efficacy, and treatment outcomes.

We cordially invite you to contribute to this Special Issue to advance our knowledge of SARS-CoV-2 and determine the means to overcome the pandemic.



[mdpi.com/si/125244](https://mdpi.com/si/125244)

# **Special Issue**